Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis

Background: In patients with neuroendocrine liver metastasis (NELM), liver transplantation (LT) is an alternative to liver resection (LR), although the choice of therapy remains controversial. In this multicenter study, we aim to provide novel insight in this dispute. Methods: Following a systematic literature search, 15 large international centers were contacted to provide comprehensive data on their patients after LR or LT for NELM. Survival analyses were performed with the Kaplan-Meier method, while multivariable Cox regression served to identify factors influencing survival after either transplantation or resection. Inverse probability weighting and propensity score matching was used for analyses with balanced and equalized baseline characteristics. Results: Overall, 455 patients were analyzed, including 230 after LR and 225 after LT, with a median follow-up of 97 months [95% confidence interval (CI): 85–110 months]. Multivariable analysis revealed G3 grading as a negative prognostic factor for LR [hazard ratio (HR)=2.22, 95% CI: 1.04–4.77, P=0.040], while G2 grading (HR=2.52, 95% CI: 1.15–5.52, P=0.021) and LT outside Milan criteria (HR=2.40, 95% CI: 1.16–4.92, P=0.018) were negative prognostic factors in transplanted patients. Inverse probability-weighted multivariate analyses revealed a distinct survival benefit after LT. Matched patients presented a median overall survival (OS) of 197 months (95% CI: 143–not reached) and a 73% 5-year OS after LT, and 119 months (95% CI: 74–133 months) and a 52.8% 5-year OS after LR (HR=0.59, 95% CI: 0.3–0.9, P=0.022). However, the survival benefit after LT was lost if patients were transplanted outside Milan criteria. Conclusions: This multicentric study in patients with NELM demonstrates a survival benefit of LT over LR. This benefit depends on adherence to selection criteria, in particular low-grade tumor biology and Milan criteria, and must be balanced against potential risks of LT.

[1]  S. Shrikhande,et al.  Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors , 2021, The Journal of Nuclear Medicine.

[2]  Yongmei Yin,et al.  Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[3]  V. Mazzaferro,et al.  mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. , 2020, Annals of surgery.

[4]  S. Dueland,et al.  Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence. , 2020, Journal of hepatology.

[5]  T. Hobday,et al.  Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights , 2020, OncoTargets and therapy.

[6]  M. Falconi,et al.  Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Truant,et al.  ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. , 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[8]  O. Ciccarelli,et al.  HBPD Table of Contents, Vol. 18, No. 5, 2019 , 2019, Digestive Surgery.

[9]  W. Bechstein,et al.  Surgical resection of neuroendocrine tumor liver metastases as part of multimodal treatment strategies: A propensity score matching analysis. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  T. Pawlik,et al.  Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms , 2018, Journal of Gastrointestinal Surgery.

[11]  A. Vanoli,et al.  Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study , 2018, Neuroendocrinology.

[12]  G. Rindi,et al.  The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. , 2018, Endocrinology and metabolism clinics of North America.

[13]  J. Ramage,et al.  Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. , 2018, Seminars in oncology.

[14]  J. Berlin,et al.  NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  M. Marazuela,et al.  Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). , 2018, The oncologist.

[16]  J. Mayerle,et al.  Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. , 2017, The lancet. Diabetes & endocrinology.

[17]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[18]  T. Pawlik,et al.  Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review , 2017, Surgery.

[19]  E. Nakakura,et al.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society , 2017, Pancreas.

[20]  J. Hainsworth,et al.  Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[22]  D. Raptis,et al.  Meta‐analysis of associating liver partition with portal vein ligation and portal vein occlusion for two‐stage hepatectomy , 2016, The British journal of surgery.

[23]  L. Mariani,et al.  The Long‐Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  V. Ambrosini,et al.  Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[25]  James C Yao,et al.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.

[26]  E. Krenning,et al.  ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.

[27]  P. Ruszniewski,et al.  Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study , 2016, Endocrine-related cancer.

[28]  E. Krenning,et al.  ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.

[29]  E. D. de Vries,et al.  Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Goldberg,et al.  Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes , 2015, Transplantation.

[31]  V. Mazzaferro,et al.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[32]  R. Schilsky,et al.  Recommendations for management of patients with neuroendocrine liver metastases. , 2014, The Lancet. Oncology.

[33]  G. Åkerström,et al.  Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare? , 2014, World Journal of Surgery.

[34]  F. Pruvot,et al.  Liver Transplantation for Neuroendocrine Tumors in Europe—Results and Trends in Patient Selection: A 213-Case European Liver Transplant Registry Study , 2013, Annals of surgery.

[35]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[36]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[37]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[38]  Manal M. Hassan,et al.  The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum , 2010, Pancreas.

[39]  M. Choti,et al.  Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis , 2010, Annals of Surgical Oncology.

[40]  E. Baudin,et al.  Hepatic Metastases From Neuroendocrine Tumors With a “Thin Slice” Pathological Examination: They are Many More Than You Think … , 2010, Annals of surgery.

[41]  M. Falconi,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors , 2009, Neuroendocrinology.

[42]  Kurinchi Selvan Gurusamy,et al.  Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. , 2009, The Cochrane database of systematic reviews.

[43]  A. Bockisch,et al.  Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease , 2009, The British journal of surgery.

[44]  Olga Ciccarelli,et al.  Tacrolimus Monotherapy in Liver Transplantation: One-Year Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Study , 2008, Annals of surgery.

[45]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  V. Mazzaferro,et al.  Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? , 2007, Journal of hepatology.

[47]  M. Choti,et al.  Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer , 2007, Journal of Gastrointestinal Surgery.

[48]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[49]  P. Brousse,et al.  Split liver transplantation , 2002, Steinkopff.

[50]  D. Canes,et al.  Hepatic neuroendocrine metastases: does intervention alter outcomes? , 2000, Journal of the American College of Surgeons.